Kourong Shi

Dr. Kourong Shi


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2021 in Molecules
Verified
Journal Article
Open access
PDF file
YNYi-Wen Nie
Yi-Wen Nie
YLYuan Li
Yuan Li
LLLan Luo
Lan Luo
CZChun-Yan Zhang
Chun-Yan Zhang
WFWei Fan
Wei Fan
JZJianyong Zhu
Jianyong Zhu
There are abundant natural diterpenoids in the plants of the genus Daphne from the Thymelaeaceae family, featuring a 5/7/6-tricyclic ring system and usually with an orthoester group. So far, a total of 135 diterpenoids has been isolated from the species of the genus Daphne, which could be further classified into three main types according to the substitution pattern of ring A and oxygen-containing functions at ring B. A variety of studies have demonstrated that these compounds exert a wide range of bioactivities both in vitro and in vivo including anticancer, anti-inflammatory, anti-HIV, antifertility, neurotrophic, and cholesterol-lowering effects, which is reviewed herein. Meanwhile, the fascinating structure–activity relationship is also concluded in this review in the hope of providing an easy access to available information for the synthesis and optimization of efficient drugs.

10 August 2024 in Pharmacological Research
Verified
Journal Article
Open access
CLCuiping Li
Cuiping Li
KSKourong Shi
Kourong Shi
SZSiyuan Zhao
Siyuan Zhao
JLJuan Liu
Juan Liu
QZQiaoli Zhai
Qiaoli Zhai
WFWei Fan
Wei Fan
Drug conjugates are obtained from tumor-located vectors connected to cytotoxic agents via linkers, which are designed to deliver hyper-toxic payloads directly to targeted cancer cells. These drug conjugates include antibody-drug conjugates (ADCs), peptide-drug conjugates (PDCs), small molecule-drug conjugates (SMDCs), nucleic acid aptamer-drug conjugates (ApDCs), and virus-like drug conjugate (VDCs), which show great therapeutic value in the clinic. Drug conjugates consist of a targeting carrier, a linker, and a payload. Payloads are key therapy components. Cytotoxic molecules and their derivatives derived from natural products are commonly used in the payload portion of conjugates. The ideal payload should have sufficient toxicity, stability, coupling sites, and the ability to be released under specific conditions to kill tumor cells. Microtubule protein inhibitors, DNA damage agents, and RNA inhibitors are common cytotoxic molecules. Among these conjugates, cytotoxic molecules of natural origin are summarized based on their mechanism of action, conformational relationships, and the discovery of new derivatives. This paper also mentions some cytotoxic molecules that have the potential to be payloads. It also summarizes the latest technologies and novel conjugates developed in recent years to overcome the shortcomings of ADCs, PDCs, SMDCs, ApDCs, and VDCs. In addition, this paper summarizes the clinical trials conducted on conjugates of these cytotoxic molecules over the last five years. It provides a reference for designing and developing safer and more efficient conjugates.

11 December 2025 in Drugs in R&D
Verified
Journal Article
Open access
PDF file
HSHuan Sun
Huan Sun
XHXiaoli Hou
Xiaoli Hou
QZQiuzhen Zhu
Qiuzhen Zhu
JLJuan Liu
Juan Liu
QZQiaoli Zhai
Qiaoli Zhai
KSKourong Shi
Kourong Shi
Omadacycline is a novel tetracycline with a wide range of antibacterial activity. A comprehensive understanding of the factors influencing its metabolic processes is essential to optimize its therapeutic benefits and minimize any potential negative effects. It was found that the metabolism of omadacycline does not rely on UDP-glucosyltransferase or cytochrome P450 enzymes, which gives it a clear advantage in terms of drug interactions, bioavailability, and metabolic stability. The review offers a thorough analysis of the many elements influencing the pharmacokinetics of omadacycline, including its intrinsic properties, individual differences, dietary influences, and possible drug interactions. To achieve maximum efficacy and safety in clinical practice, a thorough understanding of the pharmacokinetic properties of omadacycline is essential, which helps to better customize dosing regimens and maximize therapeutic outcomes.

13 May 2025 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
HSHuan Sun
Huan Sun
QZQiaoli Zhai
Qiaoli Zhai
JLJuan Liu
Juan Liu
KSKourong Shi
Kourong Shi
WFWei Fan
Wei Fan

2 February 2026 in Thrombosis Journal
Verified
Journal Article
Open access
PDF file
HSHuan Sun
Huan Sun
QZQiaoli Zhai
Qiaoli Zhai
BXBeiwei Xin
Beiwei Xin
LZLingyu Zhong
Lingyu Zhong
KSKourong Shi
Kourong Shi
Cancer-associated thrombosis (CAT) is a serious complication frequently observed in patients with cancer; however, its exact mechanism is not yet fully und

21 December 2024 in Investigational New Drugs
Verified
Journal Article
Closed access
SZSiyuan Zhao
Siyuan Zhao
TWTiansi Wang
Tiansi Wang
KSKourong Shi
Kourong Shi
TLTing Li
Ting Li
QZQiuzhen Zhu
Qiuzhen Zhu
WFWei Fan
Wei Fan